Nurexone Biologic Inc (NRXBF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -2,247 | -922 | -3,639 | -2,902 | -1,745 |
| Depreciation Amortization | 28 | 15 | 33 | 30 | 12 |
| Other Working Capital | -410 | -563 | 4 | 103 | -136 |
| Other Operating Activity | 294 | 5 | 661 | 461 | 350 |
| Operating Cash Flow | $-2,335 | $-1,465 | $-2,941 | $-2,308 | $-1,519 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -302 | -241 | -120 | -53 | -54 |
| Other Investing Activity | -10 | 0 | 23 | 0 | 0 |
| Investing Cash Flow | $-312 | $-241 | $-97 | $-53 | $-54 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 2,934 | 2,919 | N/A | 325 | N/A |
| Other Financing Activity | 1,508 | 1,479 | 1,132 | 717 | -9 |
| Financing Cash Flow | $4,442 | $4,398 | $1,132 | $1,042 | $-9 |
| Exchange Rate Effect | 49 | 22 | -16 | -1 | -1 |
| Beginning Cash Position | 541 | 541 | 2,463 | 2,463 | 2,463 |
| End Cash Position | 2,385 | 3,255 | 541 | 1,143 | 880 |
| Net Cash Flow | $1,844 | $2,714 | $-1,922 | $-1,320 | $-1,583 |
| Free Cash Flow | |||||
| Operating Cash Flow | -2,335 | -1,465 | -2,941 | -2,308 | -1,519 |
| Capital Expenditure | -302 | -241 | -120 | -53 | -54 |
| Free Cash Flow | -2,637 | -1,706 | -3,061 | -2,361 | -1,573 |